RBRK Stock Analysis: Rubrik | NYSE
Software - Infrastructure | NYSE, USA | Market Cap: 24.407m USD | 12M Return: 43.5% | US7811541090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 335M
Qual. Beats: 6
Rev. Trend: 99.9%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 2.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rubrik, Inc. (RBRK) is a Palo Alto-based data security software company that provides enterprise, cloud, SaaS, and unstructured data protection, along with identity recovery, cyber recovery, and data threat analytics. Its product portfolio includes AI-driven tools such as the RUBY cyber resilience agent and the SENTRYAI system health monitoring platform, plus the RUBRIK UNIVERSITY training and certification program. The company serves a broad range of industries, including financial services, healthcare, retail, energy, public sector, and technology, and holds a strategic collaboration with MEDITECH to deliver cyber resilience to healthcare cloud and on-premises environments. Originally incorporated in 2013 as Scaledata, Inc., it rebranded to Rubrik in October 2014 and went public on the NYSE in April 2024.
Sector & business model context: Rubrik is classified under the GICS Information Technology sector and Systems Software sub-industry, a category that includes providers of infrastructure, storage management, and data protection software. Like most enterprise security vendors in this segment, Rubrik generates revenue primarily through subscription-based licensing of its data protection and cyber resilience platform, which is typically delivered as a cloud-managed service.
- Subscription revenue growth drives recurring ARR expansion
- Enterprise data protection adoption accelerates across verticals
- Cloud data security competition intensifies against larger vendors
- Identity recovery services gain traction amid rising cyber threats
| Net Income: -254.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -1.39 > 1.0 |
| NWC/Revenue: 57.59% < 20% (prev 80.22%; Δ -22.63% < -1%) |
| CFO/TA 0.12 > 3% & CFO 340.1m > Net Income -254.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (204.9m) vs 12m ago 5.14% < -2% |
| Gross Margin: 80.21% > 18% (prev 77.96%; Δ 2.25% > 0.5%) |
| Asset Turnover: 58.92% > 50% (prev 45.32%; Δ 13.60% > 0%) |
| Interest Coverage Ratio: -54.62 > 6 (EBIT TTM -237.4m / Interest Expense TTM 4.35m) |
| A: 0.31 (Total Current Assets 2.27b - Total Current Liabilities 1.38b) / Total Assets 2.85b |
| B: -1.16 (Retained Earnings -3.29b / Total Assets 2.85b) |
| C: -0.09 (EBIT TTM -237.4m / Avg Total Assets 2.62b) |
| D: -0.15 (Book Value of Equity -499.4m / Total Liabilities 3.35b) |
| Altman-Z'' = -2.49 = D |
| DSRI: 0.86 (Receivables 269.2m/220.7m, Revenue 1.54b/1.08b) |
| GMI: 0.97 (GM 77.96% / 80.21%) |
| AQI: 1.01 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 1.42 (Revenue 1.54b / 1.08b) |
| TATA: -0.21 (NI -254.4m - CFO 340.1m) / TA 2.85b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at USD 120.89 with a total of 2,493,112 shares traded. Over the past week, the price has changed by +4.76%, over one month by +31.93%, over three months by +43.23% and over the past year by +43.49%.
Current recommended Stop Loss: 114.20 (which is 5.5% or 1.3 ATR below the current price).
Rubrik has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy RBRK.
- StrongBuy: 25
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 120.2 | -0.6% |
P/E Forward = 625.0
P/S = 15.8264
Revenue TTM = 1.54b USD
EBIT TTM = -237.4m USD
EBITDA TTM = -185.2m USD
Long Term Debt = 1.13b USD (from longTermDebt, last quarter)
Short Term Debt = 14.6m USD (from shortTermDebt, two quarters ago)
Debt = 1.15b USD (from shortLongTermDebtTotal, last quarter) + Leases 16.7m
Net Debt = 516.1m USD (calculated: Debt 1.15b - CCE 633.5m)
Enterprise Value = 24.9b USD (24.4b + Debt 1.15b - CCE 633.5m)
Interest Coverage Ratio = -54.62 (Ebit TTM -237.4m / Interest Expense TTM 4.35m)
EV/FCF = -163.0x (Enterprise Value 24.9b / FCF TTM -152.9m)
FCF Yield = -0.61% (FCF TTM -152.9m / Enterprise Value 24.9b)
FCF Margin = -9.92% (FCF TTM -152.9m / Revenue TTM 1.54b)
Net Margin = -16.50% (Net Income TTM -254.4m / Revenue TTM 1.54b)
Gross Margin = 80.21% ((Revenue TTM 1.54b - Cost of Revenue TTM 305.3m) / Revenue TTM)
Gross Margin QoQ = 78.44% (prev 80.55%)
Tobins Q-Ratio = 8.76 (Enterprise Value 24.9b / Total Assets 2.85b)
Interest Expense / Debt = 0.38% (Interest Expense 4.35m / Debt 1.15b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -187.6m (EBIT -237.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.62 (Total Current Assets 2.27b / Total Current Liabilities 1.41b)
Debt / Equity = -2.30 (negative equity) (Debt 1.15b / totalStockholderEquity, last quarter -499.4m)
Debt / EBITDA = -2.79 (negative EBITDA) (Net Debt 516.1m / EBITDA -185.2m)
Debt / FCF = -3.38 (negative FCF - burning cash) (Net Debt 516.1m / FCF TTM -152.9m)
Total Stockholder Equity = -506.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.72% (Net Income -254.4m / Total Assets 2.85b)
RoE = 50.26% (negative equity) (Net Income TTM -254.4m / Total Stockholder Equity -506.2m)
RoCE = -37.88% (EBIT -237.4m / Capital Employed (Equity -506.2m + L.T.Debt 1.13b))
RoIC = -13.55% (negative operating profit) (NOPAT -187.6m / Invested Capital 1.38b)
WACC = 11.60% (E(24.4b)/V(25.6b) * Re(12.13%) + D(1.15b)/V(25.6b) * Rd(0.38%) * (1-Tc(0.21)))
Discount Rate = 12.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.64 | Cagr: 6.83%
[DCF] Fair Price = unknown (Cash Flow -152.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.02 | # QB: 6
Revenue Correlation: 99.88 | Revenue CAGR: 43.94% | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-10-31): EPS=0.08 | Chg30d=+46.17% | Revisions=+75% | Analysts=26
EPS current Year (2027-01-31): EPS=0.50 | Chg30d=+59.88% | Revisions=+87% | GrowthEPS=+5132.5% | GrowthRev=+28.4%
EPS next Year (2028-01-31): EPS=0.77 | Chg30d=+17.98% | Revisions=+77% | GrowthEPS=+52.5% | GrowthRev=+21.5%
[Analyst] Revisions Ratio: +88% (up=54, down=2)